![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA APPROVES ACTAVIS' GENERIC MELOXICAM
FDA APPROVES ACTAVIS' GENERIC MELOXICAM
August 7, 2006
Actavis has received approval from the FDA to market generic meloxicam tablets. Distribution of the product has already started.
Meloxicam, the generic equivalent of Boehringer Ingelheim's Mobic Tablets, are available in both 7.5-mg and 15-mg strengths. Meloxicam is used to treat signs and symptoms of osteoarthritis and rheumatoid arthritis.
Annual brand sales of meloxicam in the U.S. were approximately $1.1 billion in 2005.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct